CD47 and acute myeloid leukemia: Other anti-CD47 agents that are currently being studied in AML, combined with AZA and VEN include DSP107 (NCT04937166) and SL-172154 (NCT05275439), whereas a phase 1b study (NCT04485052) of IB188 (letaplimab) plus AZA in AML was suspended.